These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31901125)

  • 1. The neutrophil-to-lymphocyte ratio as a marker of peripheral inflammation in progressive supranuclear palsy: a retrospective study.
    Inci I; Kusbeci OY; Eskut N
    Neurol Sci; 2020 May; 41(5):1233-1237. PubMed ID: 31901125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-to-lymphocyte ratio as a novel-potential marker for predicting prognosis of Bell palsy.
    Bucak A; Ulu S; Oruc S; Yucedag F; Tekin MS; Karakaya F; Aycicek A
    Laryngoscope; 2014 Jul; 124(7):1678-81. PubMed ID: 24307612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-lymphocyte ratio (NLR) at boundaries of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS).
    Alster P; Madetko N; Friedman A
    Neurol Neurochir Pol; 2021; 55(1):97-101. PubMed ID: 33315235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
    Nigro S; Morelli M; Arabia G; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A
    Parkinsonism Relat Disord; 2017 Aug; 41():31-36. PubMed ID: 28487107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
    Salvatore C; Cerasa A; Castiglioni I; Gallivanone F; Augimeri A; Lopez M; Arabia G; Morelli M; Gilardi MC; Quattrone A
    J Neurosci Methods; 2014 Jan; 222():230-7. PubMed ID: 24286700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease.
    Quattrone A; Morelli M; Nigro S; Quattrone A; Vescio B; Arabia G; Nicoletti G; Nisticò R; Salsone M; Novellino F; Barbagallo G; Le Piane E; Pugliese P; Bosco D; Vaccaro MG; Chiriaco C; Sabatini U; Vescio V; Stanà C; Rocca F; Gullà D; Caracciolo M
    Parkinsonism Relat Disord; 2018 Sep; 54():3-8. PubMed ID: 30068492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined blood Neurofilament light chain and third ventricle width to differentiate Progressive Supranuclear Palsy from Parkinson's Disease: A machine learning study.
    Bianco MG; Cristiani CM; Scaramuzzino L; Sarica A; Augimeri A; Chimento I; Buonocore J; Parrotta EI; Quattrone A; Cuda G; Quattrone A
    Parkinsonism Relat Disord; 2024 Jun; 123():106978. PubMed ID: 38678852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midbrain area for differentiating Parkinson's disease from progressive supranuclear palsy.
    Ghourchian S; Mousavi A; Zamani B; Shahidi G; Rohani M
    Clin Neurol Neurosurg; 2019 Aug; 183():105383. PubMed ID: 31181432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Dry Eye Disease.
    Celik T
    Ocul Immunol Inflamm; 2018; 26(8):1219-1222. PubMed ID: 28910561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study.
    Manna I; Quattrone A; De Benedittis S; Vescio B; Iaccino E; Quattrone A
    Parkinsonism Relat Disord; 2021 Dec; 93():77-84. PubMed ID: 34839044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome.
    Ahn JH; Kim M; Kim JS; Youn J; Jang W; Oh E; Lee PH; Koh SB; Ahn TB; Cho JW
    Parkinsonism Relat Disord; 2019 Sep; 66():80-86. PubMed ID: 31307918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson's disease.
    Liu Z; Fan Q; Wu S; Wan Y; Lei Y
    Lipids Health Dis; 2021 Apr; 20(1):35. PubMed ID: 33874966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
    Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls.
    Ondo W; Warrior D; Overby A; Calmes J; Hendersen N; Olson S; Jankovic J
    Arch Neurol; 2000 Oct; 57(10):1464-9. PubMed ID: 11030799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of neutrophil-lymphocyte ratio (NLR) in Parkinson's disease subtypes.
    Ataç Uçar C; Gökçe Çokal B; Ünal Artık HA; İnan LE; Yoldaş TK
    Neurol Sci; 2017 Feb; 38(2):287-293. PubMed ID: 27837368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson's disease.
    Azuma M; Hirai T; Nakaura T; Kitajima M; Yamashita S; Hashimoto M; Yamada K; Uetani H; Yamashita Y; Wang Y
    J Neurol Sci; 2019 Nov; 406():116443. PubMed ID: 31634718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy.
    Seki M; Seppi K; Mueller C; Potrusil T; Goebel G; Reiter E; Nocker M; Steiger R; Wildauer M; Gizewski ER; Wenning GK; Poewe W; Scherfler C
    Parkinsonism Relat Disord; 2018 Apr; 49():81-87. PubMed ID: 29463454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
    Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
    J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy].
    Yoshita M; Hayashi M; Hirai S
    Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widespread diffusion changes differentiate Parkinson's disease and progressive supranuclear palsy.
    Talai AS; Sedlacik J; Boelmans K; Forkert ND
    Neuroimage Clin; 2018; 20():1037-1043. PubMed ID: 30342392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.